FOSTER CITY, Calif. - Gilead Sciences said its anti-viral drug Veklury, also known as remdesivir, has shown promise in lowering the risk of hospitalization among certain COVID-19 patients.Data from Phase 3 of clinical trials found remdesivir to be 87% effective at reducing hospitalizations in high-risk patients who were diagnosed early."Antiviral medications provide maximal benefit when used early in the disease course.
Last summer, data from clinical trials demonstrated the benefit of remdesivir in patients hospitalized with COVID-19, even when not yet requiring oxygen.
These latest data show remdesivir’s potential to help high-risk patients recover before they get sicker and stay out of the hospital altogether," Dr.